Arrow Pharma acquires Australian operations of Amneal Pharma
NEW DELHI: Drug firm Strides Shasun today said its arm Arrow Pharmaceuticals has acquired Australian operations of Amneal Pharmaceuticals for a total consideration of AUD 17 million (over Rs 85 crore).
The acquisition would accelerate Arrow's market reach and will help in attaining a leadership position in the Australian generics market, Strides Shasun said in a statement.
Under the terms of the agreement, Arrow Pharmaceuticals will acquire 100 per cent of the issued capital of Amneal Pharmaceutical Pty Ltd Australia, it added.
"Arrow will incur an amount of AUD 17 million towards consideration, working capital and other estimated acquisition and integration related costs," Strides Shasun said.
Arrow Pharmaceuticals is a subsidiary of Strides Pharma Global Pte Ltd, Singapore, it added.
Commenting on the development, Arrow Pharmaceuticals Chairman Dennis Bastas said: "The acquisition of Amneal's Australian operations further expands our customer footprint."
Bringing Amneal's customer base into the network of supporting pharmacies further accelerates the current growth and strengthens the offering the company bring to all its customers, he added.
Shares of Strides Shasun today closed at Rs 908.45 per scrip on BSE, down 0.53 per cent from the previous close.